NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
Novocure, GmbH · Decision date Apr 8, 2011
What did the FDA approve?
FDA records P100034 as an original PMA application. The recorded decision is approval, dated Apr 8, 2011.
FDA approval order statement
APPROVAL FOR THE NOVOTTF-100A SYSTEM. THE DEVICE IS INDICATED FOR TREATMENT OF ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY- CONFIRMED GLIOBLASTOMA MULTIFORME, FOLLOWING HISTOLOGICALLY- OR RADIOLOGICALLY- CONFIRMED RECURRENCE IN THE SUPRATENTORIAL REGION OF THE BRAIN AFTER RECEIVING CHEMOTHERAPY. THE DEVICE IS INTENDED TO BE USED AS A MONOTHERAPY, AND IS INTENDED AS AN ALTERNATIVE TO STANDARD MEDICAL THERAPY FOR GBM AFTER SURGICAL AND RADIATION OPTIONS HAVE BEEN EXHAUSTED.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Apr 8, 2011
Regulatory record facts
- Identifier
- P100034
- Regulatory pathway
- Premarket approval application
- Applicant
- Novocure, GmbH
- Product code
- NZK
- Decision code
- APPR
- Decision date
- Apr 8, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, low electric field, tumor treatment.
- Applicant
- Novocure, GmbH
- Product code
- NZK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P100034 received
Application receipt date recorded by FDA.
P100034 · FDA decision
APPR
P100034/S041 · Related supplement
Optune Gio - Maxpoint Version 2.0
P100034/S043 · Related supplement
Optune Gio
P100034/S044 · Related supplement
Optune HFE Transducer Array Soft Part Components
P100034/S042 · Related supplement
Optune Gio
P100034/S046 · Related supplement
Optune HFE Transducer Arrays
P100034/S045 · Related supplement
Novocure GmbHs Optune Gio
Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune Gio - Maxpoint Version 2.0P100034/S041 | Novocure, GmbH | PMA supplement | Oct 23, 2025 | FDA |
Optune GioP100034/S043 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune HFE Transducer Array Soft Part ComponentsP100034/S044 | Novocure, GmbH | PMA supplement | Apr 9, 2026 | FDA |
Optune GioP100034/S042 | Novocure, GmbH | PMA supplement | Jun 4, 2026 | FDA |
Optune HFE Transducer ArraysP100034/S046 | Novocure, GmbH | PMA supplement | Sep 16, 2026 | FDA |
Novocure GmbHs Optune GioP100034/S045 | Novocure, GmbH | PMA supplement | Sep 18, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P100034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




